Xylem (NYSE: XYL ) reported earnings on July 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Xylem met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share contracted significantly. GAAP earnings per share shrank significantly.
Margins dropped across the board.
Xylem chalked up revenue of $960.0 million. The nine analysts polled by S&P Capital IQ foresaw net sales of $967.9 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.36. The 13 earnings estimates compiled by S&P Capital IQ anticipated $0.45 per share. Non-GAAP EPS of $0.36 for Q2 were 27% lower than the prior-year quarter's $0.49 per share. GAAP EPS of $0.25 for Q2 were 48% lower than the prior-year quarter's $0.48 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 38.6%, 100 basis points worse than the prior-year quarter. Operating margin was 9.5%, 450 basis points worse than the prior-year quarter. Net margin was 4.8%, 440 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $985.7 million. On the bottom line, the average EPS estimate is $0.52.
Next year's average estimate for revenue is $3.87 billion. The average EPS estimate is $1.82.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 80 members out of 84 rating the stock outperform, and four members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give Xylem a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Xylem is outperform, with an average price target of $30.21.
Looking for alternatives to Xylem? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Xylem to My Watchlist.